Adocia: Number of ADOCIA shares and voting rights as of March 31, 2022


Lyon, France–(BUSINESS WIRE)–Regulatory news:

In accordance with the provisions of Article L. 233-8 II of the French Commercial Code and Article 223-16 of the Stock Exchange Code (Financial Markets Authorityor “AMF”) charter ADOCIA SA, (Paris:ADOC) French company anonimous society (company), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical company specializing in the treatment of diabetes, obesity and metabolic diseases with innovative formulations of approved proteins, publishes its total number of shares in circulation as well as its voting rights as of March 31st2022.



Total number of

outstanding shares

Total number


right to vote (1)

Total number of

exercisable vote

rights (2)






*including 447,659 new shares resulting from the conversion of 1,874,500 bonds convertible into shares (OC 1023) issued by the Company on October 26, 2021, the main characteristics of which are described in its press release of the same day.

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.

(2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares with suspended voting rights, in this case the shares held by the Company under a of liquidity.

About Adocia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, mainly diabetes and obesity. The company has a broad pipeline of drug candidates based on three proprietary technology platforms:

1) The BioChaperon® technology for the development of next-generation insulins and products combining insulins with other classes of hormones; 2) Oral peptide delivery technology; 3) An immunoprotective biomaterial for cell transplantation with a first application in pancreatic cell transplantation in patients with “fragile” diabetes.

Adocia holds more than 25 patent families and has been ranked 4and and 7and in the SME ranking of the National Institute of Industrial Property (INPI) on the number of patents filed, respectively in 2019 and 2020.

Based in Lyon, the company has approximately 125 employees. Adocia is listed on EuronextMT Paris Market (Euronext: ADOC; ISIN: FR0011184241).


This press release contains certain forward-looking statements regarding Adocia and its business. These forward-looking statements are based on assumptions that Adocia believes to be reasonable. However, there can be no assurance that the estimates contained in these forward-looking statements will materialize, as these estimates are subject to numerous risks, including those set out in the “Risk Factors” section of the universal registration document that has been filed. with the Autorité des marchés financiers on April 20, 2021 (a copy of which is available on, in particular the uncertainties related to research and development, future clinical data, analyzes and the evolution of the economic context, the financial markets and the markets in which Adocia operates.

The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered material by Adocia at this time. The occurrence of any or all of these risks could cause the actual results, financial conditions, performance or achievements of Adocia to differ materially from those referred to in the forward-looking statements.

This press release and the information it contains do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction whatsoever.


Comments are closed.